NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy
N-methyl-D-aspartate receptors (NMDAR) play a central role in epileptogensis and NMDAR antagonists have been shown to have antiepileptic effects in animals and humans. Despite significant progress in the development of antiepileptic therapies over the previous 3 decades, a need still exists for nove...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/19038/1/NMDA_receptor_antagonism_with_novel_indolyl.pdf |
| _version_ | 1796960601530957824 |
|---|---|
| author | Rothan, H.A. Amini, E. Faraj, F.L. Golpich, M. Teoh, T.C. Gholami, K. Yusof, R. |
| author_facet | Rothan, H.A. Amini, E. Faraj, F.L. Golpich, M. Teoh, T.C. Gholami, K. Yusof, R. |
| author_sort | Rothan, H.A. |
| collection | UM |
| description | N-methyl-D-aspartate receptors (NMDAR) play a central role in epileptogensis and NMDAR antagonists have been shown to have antiepileptic effects in animals and humans. Despite significant progress in the development of antiepileptic therapies over the previous 3 decades, a need still exists for novel therapies. We screened an in-house library of small molecules targeting the NMDA receptor. A novel indolyl compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, (DDBM) showed the best binding with the NMDA receptor and computational docking data showed that DDBM antagonised the binding sites of the NMDA receptor at lower docking energies compared to other molecules. Using a rat electroconvulsive shock (ECS) model of epilepsy we showed that DDBM decreased seizure duration and improved the histological outcomes. Our data show for the first time that indolyls like DDBM have robust anticonvulsive activity and have the potential to be developed as novel anticonvulsants. |
| first_indexed | 2024-03-06T05:47:05Z |
| format | Article |
| id | um.eprints-19038 |
| institution | Universiti Malaya |
| language | English |
| last_indexed | 2024-03-06T05:47:05Z |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | um.eprints-190382018-08-30T06:04:59Z http://eprints.um.edu.my/19038/ NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy Rothan, H.A. Amini, E. Faraj, F.L. Golpich, M. Teoh, T.C. Gholami, K. Yusof, R. Q Science (General) R Medicine N-methyl-D-aspartate receptors (NMDAR) play a central role in epileptogensis and NMDAR antagonists have been shown to have antiepileptic effects in animals and humans. Despite significant progress in the development of antiepileptic therapies over the previous 3 decades, a need still exists for novel therapies. We screened an in-house library of small molecules targeting the NMDA receptor. A novel indolyl compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, (DDBM) showed the best binding with the NMDA receptor and computational docking data showed that DDBM antagonised the binding sites of the NMDA receptor at lower docking energies compared to other molecules. Using a rat electroconvulsive shock (ECS) model of epilepsy we showed that DDBM decreased seizure duration and improved the histological outcomes. Our data show for the first time that indolyls like DDBM have robust anticonvulsive activity and have the potential to be developed as novel anticonvulsants. Nature Publishing Group 2017 Article PeerReviewed application/pdf en http://eprints.um.edu.my/19038/1/NMDA_receptor_antagonism_with_novel_indolyl.pdf Rothan, H.A. and Amini, E. and Faraj, F.L. and Golpich, M. and Teoh, T.C. and Gholami, K. and Yusof, R. (2017) NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy. Scientific Reports, 7 (1). p. 45540. ISSN 2045-2322, DOI https://doi.org/10.1038/srep45540 <https://doi.org/10.1038/srep45540>. http://dx.doi.org/10.1038/srep45540 doi:10.1038/srep45540 |
| spellingShingle | Q Science (General) R Medicine Rothan, H.A. Amini, E. Faraj, F.L. Golpich, M. Teoh, T.C. Gholami, K. Yusof, R. NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title | NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title_full | NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title_fullStr | NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title_full_unstemmed | NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title_short | NMDA receptor antagonism with novel indolyl, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, reduces seizures duration in a rat model of epilepsy |
| title_sort | nmda receptor antagonism with novel indolyl 2 1 1 dimethyl 1 3 dihydro benzo e indol 2 ylidene malonaldehyde reduces seizures duration in a rat model of epilepsy |
| topic | Q Science (General) R Medicine |
| url | http://eprints.um.edu.my/19038/1/NMDA_receptor_antagonism_with_novel_indolyl.pdf |
| work_keys_str_mv | AT rothanha nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT aminie nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT farajfl nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT golpichm nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT teohtc nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT gholamik nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy AT yusofr nmdareceptorantagonismwithnovelindolyl211dimethyl13dihydrobenzoeindol2ylidenemalonaldehydereducesseizuresdurationinaratmodelofepilepsy |